Hematology

CAR-T and BsAb therapies revolutionize multiple myeloma treatment but pose infection risks, necessitating vigilant monitoring and tailored prevention strategies.

RSV infections in multiple myeloma patients delay treatment but do not increase mortality, highlighting the need for further research on infection management.

Expert shares notable findings presented at the 2025 IMS Annual Meeting.

Revumenib was approved for adults and pediatric patients 1 year and older with relapsed or refractory acute myeloid leukemia.

The move emphasizes the need for vigilant monitoring.

Medicaid expansion enhances 5-year cancer survival rates in rural and high-poverty areas, highlighting the importance of financial support for better health outcomes.

Frail patients with multiple myeloma (MM) can safely reduce dexamethasone use, enhancing treatment outcomes without increasing infection risks.

Cevostamab shows promise as a post-CAR T therapy for relapsed/refractory multiple myeloma, enhancing MRD-negative responses and improving patient outcomes.

Etentamig shows promise in managing infections for relapsed/refractory multiple myeloma.

Anitocabtagene autoleucel shows impressive efficacy and safety in treating relapsed/refractory multiple myeloma, achieving a 97% overall response rate.

New IMWG/IMS guidelines enhance risk assessment for multiple myeloma, revealing daratumumab's impact on patient outcomes in real-world settings.

Pharmacists navigate the evolving hematology-oncology landscape, utilizing genetic insights and innovative therapies to enhance patient care.

New research links rapid CAR T-cell expansion to delayed neurotoxicity in patients with multiple myeloma.

Elranatamab enhances MRD negativity in relapsed/refractory multiple myeloma post idecabtagene vicleucel, promising improved treatment outcomes.

Belantamab mafodotin with bortezomib shows promising survival benefits for lenalidomide-refractory multiple myeloma patients.

Idecabtagene vicleucel shows a lower infection risk than other BCMA therapies for multiple myeloma.

Linvoseltamab combined with carfilzomib shows promising results in treating relapsed/refractory multiple myeloma.

Experts discuss the potential of linvoseltamab in treating high-risk smoldering multiple myeloma, highlighting promising early trial results and response rates.

Intravenous immunoglobulin (IVIG) treatment significantly reduces infection rates in multiple myeloma patients receiving BCMA bispecific antibodies, showcasing its clinical benefits.

Teclistamab and other bispecific antibodies enhance multiple myeloma treatment but significantly increase infection risks, necessitating proactive management strategies.

Teclistamab shows promising results in newly diagnosed multiple myeloma, enhancing tolerability and achieving high rates of minimal residual disease negativity.

Elranatamab combined with daratumumab and lenalidomide shows promising results for treating newly diagnosed multiple myeloma, enhancing patient outcomes.

The 2025 International Myeloma Society Annual Meeting unveils crucial updates to IMWG guidelines, enhancing response assessment and treatment strategies for multiple myeloma.

Cutting-edge insights and expert discussions on multiple myeloma will be presented at the 2025 IMS Annual Meeting in Toronto, shaping future treatment standards.